Fitch Places Allergan's Ratings on Positive Watch Following Pfizer Merger Announcement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Teva Pharma (TEVA), Heptares Enter Migraine-Focused Drug-Discovery, Licensing Agreement
November 25, 2015 7:05 AM ESTTeva Pharma (NYSE: TEVA) and Heptares Therapeutics , a wholly owned subsidiary of Sosei Group Corporation announce that they have entered into a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the... More
